ECT Schizophrenia Serotonin Study
NCT00278668 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 15
Last updated 2008-05-21
Summary
We suggest to investigate serotonin uptake in schizophrenia patients receiving ECT
Conditions
Sponsors & Collaborators
-
Sha'ar Menashe Mental Health Center
lead OTHER
Principal Investigators
-
Avi Peled, MD · Shaar Menashe MHC
-
Ilan Modai, M.D. MHA · Shaar Menashe
-
Moshe Rehavi, Ph.D. · TAU
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-10-31
- Completion
- 2006-10-31
More Related Trials
-
Flexible Dose Titration Add-on Study to Treat Major Depressive Disorder
NCT00593879 ·Status: COMPLETED ·Phase: PHASE2
-
Electroconvulsive Therapy and Concomitant Lithium in Depressive Disorder: A Pilot Study
NCT05923476 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Mood Effects of Serotonin Agonists
NCT03790358 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder
NCT00252330 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder
NCT00252356 ·Status: COMPLETED ·Phase: PHASE3
-
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
NCT04123314 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Ketamine's Effect Changes the Cortical Electrophysiological Activity Related to Semantic Affective Dimension of Pain
NCT03915938 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
The Neurobiological Effect of 5-HT2AR Modulation
NCT03289949 ·Status: RECRUITING ·Phase: PHASE1
-
Neural Circuit Effects of Ketamine in Depression
NCT06213324 ·Status: RECRUITING ·Phase: PHASE4
-
Behavioral and Electrophysiological Effects of Ketamine in Treatment-Resistant Depression
NCT04239963 ·Status: COMPLETED
-
Mood Effects of Serotonin Agonists: Depression
NCT07017478 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
The Effect of SSRIs on Threat of Shock Potentiated Neural Circuitry
NCT07074652 ·Status: COMPLETED ·Phase: NA
-
A Study of Participants With Moderate or Severe Major Depressive Disorder (MDD) Requiring Urgent Symptom Control in a Psychiatric Emergency
NCT04829669 ·Status: WITHDRAWN
-
Study of Escitalopram in Adult Patients With Major Depressive Disorder
NCT00108979 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)
NCT00035295 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Brain Response to Emotional Pictures Using a Magnetic Resonance Imaging (fMRI) While on Escitalopram
NCT00707863 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Electrophysiological Markers of Antidepressants in Major Depressive Disorder
NCT06532604 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)
NCT00034944 ·Status: COMPLETED ·Phase: PHASE3
-
Quantitative Electroencephalogram (QEEG) Predictors of Response to Psychotherapy Versus Antidepressant Treatment in Depression
NCT00824044 ·Status: COMPLETED ·Phase: PHASE4
-
Transcranial Magnetic Stimulation Study of Cortical Excitability as Marker of Antidepressant Response: EXCIPSY Study
NCT03606850 ·Status: UNKNOWN ·Phase: NA
-
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)
NCT00042029 ·Status: COMPLETED ·Phase: PHASE3
-
Brain Energy Metabolism in Individuals With Major Depressive Disorder Receiving Escitalopram
NCT00183677 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive Disorder
NCT00432614 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density
NCT04630964 ·Status: COMPLETED ·Phase: PHASE2
-
Contact: Developing New Clinical Management Strategies
NCT03812588 ·Status: COMPLETED ·Phase: PHASE4